In patients with moderate to severe Crohn's disease, upadacitinib outperformed a placebo.

Published Date: 07 Jun 2023

According to a study printed in the May 25 issue of the New England Journal of Medicine, upadacitinib induction and maintenance therapy are superior to placebo for patients with moderate-to-severe Crohn disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Study reveals increase in late-stage breast cancer diagnoses in US

5.

Prostate cancer Q&A: Improving detection and reducing overtreatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot